Literature DB >> 6327902

Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins.

A J Morgan, M A Epstein, J R North.   

Abstract

The effectiveness of immunisation of mice, rabbits, and cotton-top tamarins with small amounts of EB virus MA glycoprotein gp340 , incorporated into artificial liposomes, has been compared using various routes of injection with or without additional adjuvants. Liposomes containing gp340 gave specific high titre antibodies after i.p. or i.v. administration, and the addition of lipid A to the liposomes resulted in a significant enhancement of the response. Antibodies generated by the above procedure were virus neutralising and bound gp340 specifically. These findings indicate an advantageous approach for use with a prototype vaccine for the prevention of EB virus infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327902     DOI: 10.1002/jmv.1890130310

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

Review 1.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.

Authors:  M A Epstein; B J Randle; S Finerty; J K Kirkwood
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

3.  Vaccine advances.

Authors:  J W Smith
Journal:  Arch Dis Child       Date:  1986-06       Impact factor: 3.791

4.  Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; L Q Tam; S P Chang; S E Case; C Hashiro; W A Siddiqui; T Shiba; S Kusumoto; S Kotani
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

5.  Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Authors:  Gabriela M Escalante; Lorraine Z Mutsvunguma; Murali Muniraju; Esther Rodriguez; Javier Gordon Ogembo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

6.  Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen.

Authors:  R L Richards; M D Hayre; W T Hockmeyer; C R Alving
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

7.  A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.

Authors:  Xinle Cui; Zhouhong Cao; Goutam Sen; Gouri Chattopadhyay; Deborah H Fuller; James T Fuller; Dustin M Snapper; Andrew L Snow; James J Mond; Clifford M Snapper
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

Review 8.  The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.

Authors:  Cong Sun; Xin-Chun Chen; Yin-Feng Kang; Mu-Sheng Zeng
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

9.  Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge.

Authors:  Xinle Cui; Zhouhong Cao; Yuriko Ishikawa; Sara Cui; Ken-Ichi Imadome; Clifford M Snapper
Journal:  Vaccines (Basel)       Date:  2021-03-19

Review 10.  Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.

Authors:  Xinle Cui; Clifford M Snapper
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.